Elyxium Wealth’s Novo Nordisk NVO Stock Holding History

Elyxium Wealth’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-926	Closed	-$47.1K	–	904
2025 Q4	$47.1K	Buy	+926	New	+$47.4K	0.01%	369

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Elyxium Wealth's NVO Position: Q1 2026 in Review

Elyxium Wealth sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 926 shares — an estimated $47.1K sold.

Elyxium Wealth first reported a position in NVO in Q4 2025 and held it in 1 quarter. The position peaked at $47.1K in Q4 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Elyxium Wealth reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
Elyxium Wealth sold 926 Novo Nordisk shares in Q1 2026, an estimated $47.1K.
Elyxium Wealth first reported a position in Novo Nordisk in Q4 2025 and held it in 1 quarter.
Elyxium Wealth's Novo Nordisk position peaked at $47.1K in Q4 2025.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Elyxium Wealth's 13F filing for Q1 2026, filed 6 May 2026.